ClinicalTrials.govpublic full text
Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy
myeloid leukemia, chronic, nilotinib , suboptimal response , imatinib, interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 982140
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.